pac1 receptor antagonist (Tocris)
Structured Review

Pac1 Receptor Antagonist, supplied by Tocris, used in various techniques. Bioz Stars score: 93/100, based on 39 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pac1 receptor antagonist/product/Tocris
Average 93 stars, based on 39 article reviews
Images
1) Product Images from "Investigation of the Role of Pituitary Adenylate Cyclase-Activating Peptide (PACAP) and Its Type 1 (PAC1) Receptor in Uterine Contractility during Endometritis in Pigs"
Article Title: Investigation of the Role of Pituitary Adenylate Cyclase-Activating Peptide (PACAP) and Its Type 1 (PAC1) Receptor in Uterine Contractility during Endometritis in Pigs
Journal: International Journal of Molecular Sciences
doi: 10.3390/ijms23105467
Figure Legend Snippet: Relative pituitary adenylate cyclase-activating peptide receptor (PAC1R) mRNA transcript abundances in the myometrial layer of gilts from the control (CON), saline (SAL) and E. coli ( E. coli ) groups, estimated by real-time PCR. Relative PAC1R mRNA transcript abundances are expressed as the mean ± SEM of ratios in relation to glyceraldehyde-3-phosphate dehydrogenase (GAPDH).
Techniques Used: Control, Saline, Real-time Polymerase Chain Reaction
Figure Legend Snippet: Relative pituitary adenylate cyclase-activating peptide receptor (PAC1R) protein abundances in the myometrial layer of gilts from the control (CON), saline (SAL) and E. coli ( E. coli ) groups, estimated by Western blot analysis. The relative PAC1R protein abundances are expressed as the mean ± SEM of ratios in relation to glyceraldehyde-3-phosphate dehydrogenase (GAPDH). The blot with representative bands for each group is presented in . * p < 0.05, *** p < 0.001 compared between groups.
Techniques Used: Control, Saline, Western Blot
Figure Legend Snippet: Representative pictures show pituitary adenylate cyclase-activating peptide receptor (PAC1R) immunostaining in the myometrial layer of gilts from the control (CON), saline (SAL) and E. coli ( E. coli ) groups. Positive immunoreaction to PAC1R is visible in muscle cells and arteries (endothelium, muscle layer) of the myometrium of the control ( A ), saline-injected ( B ) and inflamed ( C ) uteri. Negative control (NC) for PAC1R ( D ) was obtained by omitting the primary antibody. MMC—myometrial muscle cells; A—artery. The scale bar of each image is 50 µm in length.
Techniques Used: Immunostaining, Control, Saline, Injection, Negative Control
Figure Legend Snippet: Influence of pituitary adenylate cyclase-activating peptide (PACAP) alone ( A , C ) and PACAP receptor (PAC1R) antagonist with PACAP ( B , D ) on the contractile amplitude in the myometrium ( A , B ) and endometrium/myometrium ( C , D ) strips of gilts from the CON (grey bars), SAL (hatched bars) and E. coli (black bars) groups. Results were calculated for five gilts in each group. The actions of the antagonist (a dose of 10 − 6 M) and particular PACAP doses are depicted as percentage (mean ± SEM) changes from the basal (pre-treatment period) amplitude taken as 100% (horizontal lines). * p < 0.05, ** p < 0.01, *** p < 0.001 compared to the basal value in each group; A p < 0.05, AA p <0.01, AAA p <0.001 between the CON and E. coli groups for the same treatment; BB p < 0.01, BBB p < 0.001 between the SAL and E. coli groups for the same treatment; C p < 0.05 between the CON and SAL groups for the same treatment; # p <0.05, ## p < 0.01, ### p < 0.001 between the antagonist with PACAP action versus PACAP action alone for the same group/tissue/PACAP dose.
Techniques Used:
Figure Legend Snippet: Influence of pituitary adenylate cyclase-activating peptide (PACAP) alone ( A , C ) and PACAP receptor (PAC1R) antagonist with PACAP ( B , D ) on the contractile frequency in the myometria ( A , B ) and endometrium/myometrium ( C , D ) strips of gilts from the CON (grey bars), SAL (hatched bars) and E. coli (black bars) groups. Results were calculated for five gilts in each group. The actions of the antagonist (a dose of 10 − 6 M) and particular PACAP doses are depicted as the percentage (mean ± SEM) change from the basal (pre-treatment period) frequency, taken as 100% (horizontal lines). * p < 0.05, ** p < 0.01, *** p < 0.001 compared to the basal value in each group; A p < 0.05, AAA p < 0.001 compared between the CON and E. coli groups for the same treatment; B p < 0.05, BBB p < 0.001 compared between the SAL and E. coli groups for the same treatment; # p < 0.05, ## p < 0.01, ### p < 0.001 compared between the antagonist with PACAP action versus PACAP action alone for the same group/tissue/PACAP dose.
Techniques Used: